A nomogram model based on clinical characteristics and immune indicators for predicting TKI treatment outcomes in CML patients
10.12007/j.issn.0258-4646.2025.08.013
- VernacularTitle:基于临床特征及免疫指标构建列线图模型预测络氨酸激酶抑制剂对慢性粒细胞白血病的疗效
- Author:
Huan WANG
1
;
Xi CHEN
;
Xiaolong LI
;
Li SHEN
;
Hongtao LIU
;
Biwei WANG
;
Hongwei ZHAO
Author Information
1. 唐山市工人医院血液科,河北唐山 063099
- Publication Type:Journal Article
- Keywords:
chronic myeloid leukemia;
tyrosine kinase inhibitor;
immune indicators;
nomogram;
efficacy
- From:
Journal of China Medical University
2025;54(8):746-753
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore a nomogram model based on clinical characteristics and immune indicators for predicting the efficacy of tyrosine kinase inhibitor(TKI)against chronic myeloid leukemia(CML).Methods Clinical data was retrospectively collected from 100 patients with CML treated with TKI between January 2021 and January 2023 in Tangshan Gongren Hospital.Patients were divided into the best response and warning/treatment failure groups according to therapeutic efficacy.Factors affecting therapeutic efficacy were analyzed using logistic regression analysis,and a nomogram model was constructed.Results The best response and warning/treatment failure groups showed significant differences in red blood cell distribution width(RDW),platelet count(PLT),ELTS score,Th 1/CD4+,Treg/CD4+ratio,white blood cell count,and absolute value of natural killer cells(P＜0.05).Logistic regression confirmed that the above indicators were influencing factors(P＜0.05),indicating that the model was meaningful,and had a high goodness of fit as well as high predictive value.Conclusion The nomogram model constructed based on RDW,PLT,and other factors can effectively predict the thera-peutic efficacy of AKI in treating CML.
